Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Leads Biotech Rebound In 2003: Product Stories Play Well

Executive Summary

Gilead Sciences is leading a new wave of biotech stocks attempting to break out of the start-up phase to become full-fledged biopharma companies

You may also be interested in...



Pfizer/Esperion Deal Reunites Lipitor Team; $1.3 Bil. Buys Two HDL Agents

Pfizer's $1.3 bil. acquisition of Esperion will reunite the Lipitor research team and give Pfizer two more chances to develop a novel mechanism anti-atherosclerotic agent

Lilly/Icos Cialis Clears FDA; 36 Hour Efficacy Claim Applies To Starting Dose

Lilly/Icos will be able to make a 36-hour efficacy claim for the 10 mg starting dose of the erectile dysfunction treatment Cialis (tadalafil)

Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive

Genentech/Xoma's psoriasis therapy Raptiva will be available by Thanksgiving at a 25% discount to a full year of Biogen's intramuscular injection formulation of Amevive

Related Content

UsernamePublicRestriction

Register

PS043211

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel